News articles about OncoSec Medical (NASDAQ:ONCS) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OncoSec Medical earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.6883847191141 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

ONCS has been the subject of several analyst reports. Maxim Group restated a “buy” rating and set a $5.00 price target on shares of OncoSec Medical in a report on Tuesday, October 10th. ValuEngine downgraded OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. OncoSec Medical presently has an average rating of “Buy” and a consensus target price of $5.33.

OncoSec Medical (ONCS) traded down $0.02 during midday trading on Tuesday, reaching $1.25. The company had a trading volume of 1,135,548 shares, compared to its average volume of 1,660,000. OncoSec Medical has a 52 week low of $0.88 and a 52 week high of $1.87.

OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.05).

COPYRIGHT VIOLATION NOTICE: “OncoSec Medical (ONCS) Receives News Sentiment Rating of 0.15” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/07/oncosec-medical-oncs-receives-news-sentiment-rating-of-0-15.html.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Insider Buying and Selling by Quarter for OncoSec Medical (NASDAQ:ONCS)

Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.